BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25017418)

  • 1. ALK expression is absent in pancreatic ductal adenocarcinoma.
    Ormanns S; Assmann G; Reu S; Gallmeier E; Bader DC; Kleespies A; Haas M; Kruger S; Heinemann V; Kirchner T; Boeck S
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1625-8. PubMed ID: 25017418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Targetable
    Singhi AD; Ali SM; Lacy J; Hendifar A; Nguyen K; Koo J; Chung JH; Greenbowe J; Ross JS; Nikiforova MN; Zeh HJ; Sarkaria IS; Dasyam A; Bahary N
    J Natl Compr Canc Netw; 2017 May; 15(5):555-562. PubMed ID: 28476735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors.
    Graham RP; Oliveira AM; Zhang L
    Pancreas; 2013 Aug; 42(6):949-51. PubMed ID: 23851431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Oncogenic
    Shimada Y; Kohno T; Ueno H; Ino Y; Hayashi H; Nakaoku T; Sakamoto Y; Kondo S; Morizane C; Shimada K; Okusaka T; Hiraoka N
    Oncologist; 2017 Feb; 22(2):158-164. PubMed ID: 28167572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
    Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
    Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
    Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
    Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
    Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
    Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
    Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
    Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.
    Shan L; Lian F; Guo L; Yang X; Ying J; Lin D
    Diagn Pathol; 2014 Jan; 9():3. PubMed ID: 24422905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
    Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
    Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic lymphoma kinase immunohistochemistry in lung adenocarcinomas: Evaluation of performance of standard manual method using D5F3 antibody.
    Jain D; Jangra K; Malik PS; Arulselvi S; Madan K; Mathur S; Sharma MC
    Indian J Cancer; 2017; 54(1):209-213. PubMed ID: 29199692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
    Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
    Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
    Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
    J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma.
    Parejo-Alonso B; Royo-García A; Espiau-Romera P; Courtois S; Curiel-García Á; Zagorac S; Villaoslada I; Olive KP; Heeschen C; Sancho P
    Biomed Pharmacother; 2023 Feb; 158():114162. PubMed ID: 36571997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
    Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M
    J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of immunohistochemistry and fluorescent
    Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
    Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
    Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX
    PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.